Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Ross S. Milne"'
Autor:
Ceejay L. Boyce, Ingrid A. Beck, Sheila M. Styrchak, Samantha R. Hardy, Jackson J. Wallner, Ross S. Milne, R. Leavitt Morrison, David E. Shapiro, Esaú C. João, Mark H. Mirochnick, Lisa M. Frenkel
Publikováno v:
PLoS ONE, Vol 17, Iss 9 (2022)
Objective To assess in ART-naïve pregnant women randomized to efavirenz- versus raltegravir-based ART (IMPAACT P1081) whether pretreatment drug resistance (PDR) with minority frequency variants (Design A case-control study design compared PDR minori
Externí odkaz:
https://doaj.org/article/6414adc493424b66ae36a468a952de97
Autor:
Ross S. Milne, Ingrid A. Beck, Molly Levine, Isaac So, Nina Andersen, Wenjie Deng, Nuttada Panpradist, James Kingoo, Catherine Kiptinness, Nelly Yatich, James N. Kiarie, Samah R. Sakr, Michael H. Chung, Lisa M. Frenkel
Publikováno v:
AIDS (London, England). 36(14)
Assess the impact of pre-treatment high-frequency and low-frequency drug-resistant HIV variants on long-term outcomes of first-line efavirenz-based antiretroviral therapy (ART).Prospective observational study.Participants' pre-treatment plasma RNA ha
Autor:
Ingrid A. Beck, Molly Levine, Christine J. McGrath, Steve Bii, Ross S. Milne, James M. Kingoo, Isaac So, Nina Andersen, Sandra Dross, Robert W. Coombs, James Kiarie, Bhavna Chohan, Samah R. Sakr, Michael H. Chung, Lisa M. Frenkel
Publikováno v:
EClinicalMedicine, Vol 18, Iss , Pp - (2020)
Background: Pre-treatment HIV-drug-resistance (PDR) to WHO-recommended 1st-line non-nucleoside reverse transcriptase inhibitors (NNRTI)-based antiretroviral treatment (ART) is increasing in low-resource communities. We evaluated the risk of PDR on tr
Externí odkaz:
https://doaj.org/article/302e55f02ef349b1a0f7c82631578d63
Autor:
James Kiarie, Bhavna Chohan, Christine J. McGrath, Ross S. Milne, Isaac So, Michael H. Chung, Ingrid A. Beck, Sandra Dross, Molly Levine, Lisa M. Frenkel, Samah R. Sakr, Catherine Kiptinness, Robert W. Coombs, Nina Andersen, Nelly Yatich
Publikováno v:
Lancet HIV
Although experts have recommended testing for pretreatment drug resistance (PDR) before antiretroviral therapy (ART) initiation, there is little evidence to support its implementation. We aimed to establish whether an inexpensive point mutation assay
Autor:
Justin D. Vrana, Parker S. Ruth, Ute Dagmar Feucht, Laddawan Laomanit, Ingrid A. Beck, Annie Wong-On-Wing, Daisy Ko, David McIntyre, Jonathan Lim, Enos Kline, Ross S. Milne, Barry R. Lutz, James J. Lai, Eric Klavins, Nicole Ngo-Giang-Huong, Ruth Kanthula, Nuttada Panpradist, Isaac So, Lisa M. Frenkel, Michael H. Chung, Nikki Higa, Theresa M. Rossouw, Jaime Soria, Gonzague Jourdain
Publikováno v:
EBioMedicine, Vol 50, Iss, Pp 34-44 (2019)
EBioMedicine
EBioMedicine
Background: HIV drug resistance (HIVDR) testing can assist clinicians in selecting treatments. However, high complexity and cost of genotyping assays limit routine testing in settings where HIVDR prevalence has reached high levels. Methods: The oligo
Autor:
Michael H. Chung, Lisa M. Frenkel, James Kiarie, Christine J. McGrath, Catherine Kiptinness, Ingrid A. Beck, Ross S. Milne, Samah R. Sakr, Molly Levine, Steve Bii, Grace John-Stewart, Bhavna Chohan, Barbra A. Richardson, Rachel A Silverman
Publikováno v:
The Journal of Infectious Diseases. 216:1569-1578
Background Pre-antiretroviral-treatment drug resistance (PDR) is a predictor of human immunodeficiency virus (HIV) treatment failure. We determined PDR prevalence and correlates in a Kenyan cohort. Methods We conducted a cross-sectional analysis of a
Autor:
Grace John-Stewart, Ross S. Milne, Rachel A Silverman, Ingrid A. Beck, Barbra A. Richardson, Christine J. McGrath, Bhavna Chohan, Samah R. Sakr, Michael H. Chung, Catherine Kiptinness, Lisa M. Frenkel
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 10, p e0223411 (2019)
PLoS ONE, Vol 14, Iss 10, p e0223411 (2019)
IntroductionDespite increased treatment availability, HIV-infected individuals continue to start antiretroviral therapy (ART) late in disease progression, increasing early mortality risk.Materials and methodsNested prospective cohort study within a r
Autor:
Thomas R Sibley, Lisa M. Frenkel, Jennifer McKernan-Mullin, Michael H. Chung, Wenjie Deng, James Kiarie, Samah R. Sakr, Rachel A Silverman, Robert W. Coombs, Ross S. Milne, Sandra Dross, Ingrid A. Beck
Publikováno v:
AIDS
OBJECTIVES Among women initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based-ART with and without a history of single-dose nevirapine (sdNVP) with or without zidovudine with or without lamivudine (ZDV with and without 3TC)
Autor:
Ross S. Milne, Molly Levine, Lisa M. Frenkel, Sandra Dross, Nina Andersen, Michael H. Chung, Samah R. Sakr, James Kiarie, Ingrid A. Beck, Isaac So, Robert W. Coombs, Steve Bii, Bhavna Chohan, Christine J. McGrath, James M. Kingoo
Publikováno v:
EClinicalMedicine, Vol 18, Iss, Pp-(2020)
EClinicalMedicine
EClinicalMedicine
Background: Pre-treatment HIV-drug-resistance (PDR) to WHO-recommended 1st-line non-nucleoside reverse transcriptase inhibitors (NNRTI)-based antiretroviral treatment (ART) is increasing in low-resource communities. We evaluated the risk of PDR on tr
Autor:
Boyce, Ceejay L1,2 (AUTHOR), Sils, Tatiana2 (AUTHOR), Milne, Ross S2 (AUTHOR), Wallner, Jackson J2 (AUTHOR), Hardy, Samantha R2 (AUTHOR), Ko, Daisy2 (AUTHOR), Wong-On-Wing, Annie2 (AUTHOR), Mackey, Malia2 (AUTHOR), Higa, Nikki2 (AUTHOR), Beck, Ingrid A2 (AUTHOR), Styrchak, Sheila M2 (AUTHOR), DeMarrais, Patricia3 (AUTHOR), Tierney, Camlin3 (AUTHOR), Fowler, Mary G4 (AUTHOR), Frenkel, Lisa M1,2,5,6 (AUTHOR) lfrenkel@uw.edu, Team, Promoting Maternal and Infant Survival Everywhere (PROMISE) Study (AUTHOR)
Publikováno v:
Open Forum Infectious Diseases. Jul2024, Vol. 11 Issue 7, p1-10. 10p.